Table 4.
Follow-up of chest CT findings
| Study | Number of patients with confirmed COVID-19 (total number of CTs if multiple CTs performed) | Follow-up data available (n) | Mean duration of follow-up CT | Follow-up (n = number of patients (% of total patients on follow-up)) |
|---|---|---|---|---|
| Huang et al [8] | 41 | NP | NP | Bilateral GGO persisted, consolidations were resolved |
| Song et al [10]* | 51 | 13 | NP | Progression in size or number of consolidations = 4/13 (31%), decrease in size = 7/13 (54%) |
| Chung et al [11] | 21 | 8 | 2.5 days | Mild progression = 5/8 (63%), Moderate progression =2/8 (25%), normal initial and follow-up CT = 1/8 (13%), improvement or severe progression = 0 |
| Pan et al [16] | 63 | 63 | 3–14 days | Progression (increase in number and size of lesions) = 54/63 (85.7%) |
| Ng et al [20] | 21 | 4 | 3–4 days | Improvement (reduction in the consolidation) = 1, normal = 1, progression = 2 (new GGO, consolidation) |
| Zhu et al [23]* | 6 | 3 | NP | Progression = 1, resorption = 2 |
| Xu et al [24]* | 50 | 30 | 3-13 days | Improvement = 28, no marked improvements = 2 |
| Li and Xia [27] | 51 | 24 | 5 | Progression = 18/24 (75.0%); improvement = 5/24 (21%) |
| Shi et al [30] | 81 | 57 | NP | Initial progression to peak level, followed by radiographic improvement (type 1) = 26 (46%), radiographic deterioration (type 2) = 18 (32%), radiographic improvement (type 3) = 8 (14%), and unchanged radiographic appearance (type 4) = 5 (9%) |
| Xu et al [31] | 90 | 52 | 3.5 days | No change = 10 (19%), disease resolution = 4 (8%), disease progression = 38 (73%) |
| Liu et al [32] | 73 | NP | NP | Improvement =12 (16%). Residual interstitial abnormalities = 4 (5.4%) |
| Guan et al [34] | 53 | 33 | 6.2 ± 2.9 days | Lesions increased = 25 (75.8%), lesions resorbed = 8 (24.2%) |
| Li et al [36] | 131 | 91 | 3.5 | Lesions absorbed = 25 (27%); no significant changes = 25 (27%), disease progression = 41 (46%) |
| Zhang et al [45]* | 28 | 28 | 7-14 days | Improvement = 13 (46.4%), unchanged appearance = 5 (17.9%), and deterioration = 6 (21.4%) |
| Yang et al [47] | 44 | NP | median = 4 days | Lesions progression = 81.82%, lesion absorption = 13.64% |
| Wang et al [48] | 114 | 16 | NP | No change = 0 (0%); lesion disappeared = 0 (0%); lesion mitigated slightly = 4 (25%); mild disease progression = 7 (43.8%); moderate disease progression = 5 (31.2%); severe disease progression = 0 (0%) |
NP, not provided
*Studies showing a greater number of disease improvements rather than progression